Vitamin K ( DrugBank: Vitamin K )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2
46	悪性関節リウマチ	2
96	クローン病	2
97	潰瘍性大腸炎	1
299	嚢胞性線維症	2

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03091569 (ClinicalTrials.gov)	March 10, 2017	21/3/2017	Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy	Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY)	Relapsing-Remitting Multiple Sclerosis	Other: Vitamin K Cream;Other: Placebo Cream	Biogen	NULL	Completed	18 Years	N/A	All	23	Phase 4	Italy
2	NCT01462318 (ClinicalTrials.gov)	November 2011	14/7/2011	An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis	A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: Midazolam;Other: Caffeine;Drug: S-warfarin;Other: Vitamin K;Drug: Omeprazole;Drug: Dextromethorphan;Biological: BIIB019 (Daclizumab)	Biogen	NULL	Completed	18 Years	65 Years	All	133	Phase 3	United States;Czech Republic;Hungary;Poland;Russian Federation

46. 悪性関節リウマチ

臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04246762 (ClinicalTrials.gov)	April 6, 2021	27/1/2020	Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4	A Phase 1, Open-label, Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4	Rheumatoid Arthritis	Drug: Olokizumab;Drug: Omeprazole;Drug: Caffeine;Drug: Warfarin+ Vitamin K;Drug: Midazolam	R-Pharm International, LLC	IQVIA RDS Ireland Ltd;Thermo Fisher Scientific	Recruiting	18 Years	70 Years	All	15	Phase 1	Bulgaria;Moldova, Republic of
2	NCT01636557 (ClinicalTrials.gov)	October 11, 2012	6/7/2012	A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis	A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Sirukumab;Drug: Midazolam;Drug: Warfarin;Drug: Vitamin K;Drug: Omeprazole;Drug: Caffeine	Janssen Research & Development, LLC	NULL	Completed	18 Years	65 Years	All	12	Phase 1	Germany;Korea, Republic of;Moldova, Republic of;South Africa

96. クローン病

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03358706 (ClinicalTrials.gov)	February 2, 2018	27/11/2017	A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis	A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis.	Crohn Disease;Ulcerative Colitis	Drug: Ustekinumab IV Infusion;Drug: Ustekinumab SC Injection;Drug: Midazolam 2 mg;Drug: Warfarin 10 mg;Drug: Vitamin K 10 mg;Drug: Omeprazole 20 mg;Drug: Dextromethorphan 30 mg;Drug: Caffeine 100 mg	Janssen Research & Development, LLC	NULL	Recruiting	18 Years	75 Years	All	57	Phase 1	United States;Belgium;Germany;United Kingdom;Austria;Denmark;Sweden
2	NCT01235325 (ClinicalTrials.gov)	July 2008	4/11/2010	The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients	The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease	Supplementation;Bone Health;Crohn's Disease	Dietary Supplement: phylloquinone (vitamin K1);Dietary Supplement: placebo	University College Cork	Health Research Board, Ireland	Completed	18 Years	70 Years	Both	70	Phase 4	Ireland

97. 潰瘍性大腸炎

臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03358706 (ClinicalTrials.gov)	February 2, 2018	27/11/2017	A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis	A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis.	Crohn Disease;Ulcerative Colitis	Drug: Ustekinumab IV Infusion;Drug: Ustekinumab SC Injection;Drug: Midazolam 2 mg;Drug: Warfarin 10 mg;Drug: Vitamin K 10 mg;Drug: Omeprazole 20 mg;Drug: Dextromethorphan 30 mg;Drug: Caffeine 100 mg	Janssen Research & Development, LLC	NULL	Recruiting	18 Years	75 Years	All	57	Phase 1	United States;Belgium;Germany;United Kingdom;Austria;Denmark;Sweden

299. 嚢胞性線維症

臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04496921 (ClinicalTrials.gov)	August 10, 2020	21/7/2020	Vitamin K Supplementation to Reduce Deficiencies in Adults With Cystic Fibrosis	Vitamin K Supplementation to Reduce Deficiencies in Adults With Cystic Fibrosis : A Pilot Study	Cystic Fibrosis	Dietary Supplement: Vitamin K supplementation, dose #1;Dietary Supplement: Vitamin K supplementation, dose #2	Institut de Recherches Cliniques de Montreal	Université de Montréal	Withdrawn	18 Years	N/A	All	0	N/A	Canada
2	EUCTR2006-000945-20-GB (EUCTR)	22/08/2006	18/09/2006	To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis	To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic Fibrosis	Cystic Fibrosis MedDRA version: 8.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis	Trade Name: Menadiol Diphosphate Product Name: Menadiol Diphosphate Product Code: Menadiol Diphosphate INN or Proposed INN: Menadiol sodium diphosphate	Barts and the London NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United Kingdom

先頭へ